Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Wyss Center
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The company is currently tackling hypometabolism in an ‘orphan’ neurological disease named Glucose Transporter 1-Deficiency Syndrome. This rare disease is characterized by a reduced entry of glucose into the brain that leads to severe symptoms in chi...
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
February 24, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Wyss Center
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : NI504
Therapeutic Area : Neurology
Study Phase : Discovery Platform
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration
Details : In the new collaboration, companies aim to generate and validate human-derived monoclonal antibodies (NI504) against Ono’s selected drug targets. Ono will obtain exclusive rights for worldwide development and commercialization of antibody products resu...
Product Name : NI504
Product Type : Antibody
Upfront Cash : Undisclosed
January 17, 2022
Lead Product(s) : NI504
Therapeutic Area : Neurology
Highest Development Status : Discovery Platform
Sponsor : Ono Pharmaceutical
Deal Size : Undisclosed
Deal Type : Collaboration